Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dcfcadd7d1a38f59c080dbb0cd5c02a3 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 |
filingDate |
2018-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2022-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b28ced7162eb8885d353ecc4a36c82d0 |
publicationDate |
2022-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-11400096-B2 |
titleOfInvention |
Small molecules for the treatment of autoimmune disorders |
abstract |
Certain embodiments are directed to methods of treating autoimmune disorders by administering P2 purnergic receptor antagonist and/or adenosine receptor antagonists. The P2 purnergic receptor antagonist being chemical analogs of adenosine receptor antagonist 8-Ethoxy-9-ethyl-9H-purin-6-amine. The adenosine receptor antagonists being chemical analogs of the non-hydrolysable ATP analog adenosine 5′[γ-thio]triphosphate (ATPγS). Certain embodiments are directed to the use of the chemical analogs to modulate IL-17 activity. |
priorityDate |
2017-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |